报价延迟最少15分钟:2026/04/16 13:18 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.6357 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.55/-0.44
|
|
企业价值
172.34M
|
| 资产负债 |
|
每股账面净值
-0.27
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
2.79M
|
|
每股收益
0.51
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants. |
